Comparative effectiveness and safety of high‐dose rivaroxaban and apixaban for atrial fibrillation: A propensity score‐matched cohort study

Observational studies assessing direct oral anticoagulant (DOACs) dosage in atrial fibrillation (AF) reported that a lower proportion of patients received high‐dose DOACs compared to those in randomized controlled trials (RCTs). Effectiveness and safety of high‐dose DOACs relative to apixaban in a real‐world AF population need to be addressed. The aim is to assess comparative effectiveness and safety of high‐dose rivaroxaban relative to apixaban.

[1]  M. Dorais,et al.  Agreement Between Administrative Database and Medical Chart Review for the Prediction of Chronic Kidney Disease G category , 2020, Canadian journal of kidney health and disease.

[2]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[3]  J. Spence.  Faculty Opinions recommendation of Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: A cohort study. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[4]  T. Martinussen,et al.  Response by Bonde and Martinussen to Letter Regarding Article, "Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort". , 2020, Circulation. Cardiovascular quality and outcomes.

[5]  J. Tardif,et al.  Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation , 2019, Pharmacotherapy.

[6]  J. Alpert.  Bleeding risk in elderly patients receiving anticoagulant therapy: Should dosage be reduced? , 2019, The American journal of medicine.

[7]  U. Schwarz,et al.  Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation , 2019, Journal of the American Geriatrics Society.

[8]  M. Reichman,et al.  Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. , 2019, The American journal of medicine.

[9]  P. Gamache,et al.  Frailty and health services use among Quebec seniors with non-hip fractures: a population-based study using adminsitrative databases , 2019, BMC Health Services Research.

[10]  P. Austin,et al.  Propensity‐score matching with competing risks in survival analysis , 2018, Statistics in medicine.

[11]  Susan Gruber,et al.  Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses , 2018, American journal of epidemiology.

[12]  L. Mbuagbaw,et al.  Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies , 2018, European Journal of Epidemiology.

[13]  J. Tardif,et al.  Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study , 2018, Clinical cardiology.

[14]  R. Testa,et al.  Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants , 2018, Journal of thrombosis and haemostasis : JTH.

[15]  G. Patti,et al.  Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation , 2018, Anatolian journal of cardiology.

[16]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.

[17]  A. Pariente,et al.  Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study , 2017, Pharmacoepidemiology and drug safety.

[18]  Claes Held,et al.  The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation , 2016, European heart journal.

[19]  L. Wilkins.  Association of atrial fibrillation with mortality and disability after ischemic stroke , 2016, Neurology.

[20]  E. Antman,et al.  Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial , 2016, Journal of the American Heart Association.

[21]  E. Antman,et al.  Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial , 2015, The Lancet.

[22]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[23]  S. Messé,et al.  Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology , 2014, Neurology.

[24]  L. Wilkins.  Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology , 2014, Neurology.

[25]  S. Yusuf,et al.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). , 2014, Journal of the American College of Cardiology.

[26]  D. Singer,et al.  Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation , 2013, Journal of the American Heart Association.

[27]  D. Singer,et al.  Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. , 2013, The American journal of cardiology.

[28]  M. O’Donnell,et al.  Association of atrial fibrillation with mortality and disability after ischemic stroke , 2013, Neurology.

[29]  Mårten Rosenqvist,et al.  Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.

[30]  G. Lip,et al.  Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report , 2012, Chest.

[31]  James Floyd,et al.  A systematic review of validated methods for identifying atrial fibrillation using administrative data , 2012, Pharmacoepidemiology and drug safety.

[32]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[33]  Peter Jüni,et al.  An overview of the objectives of and the approaches to propensity score analyses. , 2011, European heart journal.

[34]  Rajeev Chaudhry,et al.  Use of an electronic administrative database to identify older community dwelling adults at high-risk for hospitalization or emergency department visits: The elders risk assessment index , 2010, BMC health services research.

[35]  S. Yusuf,et al.  Newly identified events in the RE-LY trial. , 2010, The New England journal of medicine.

[36]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[37]  David L Buckeridge,et al.  Enhancing Pharmacosurveillance with Systematic Collection of Treatment Indication in Electronic Prescribing , 2010, Drug safety.

[38]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[39]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[40]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[41]  Peter C Austin,et al.  Report Card on Propensity-Score Matching in the Cardiology Literature From 2004 to 2006: A Systematic Review , 2008, Circulation. Cardiovascular quality and outcomes.

[42]  Independent predictors of stroke in patients with atrial fibrillation , 2007, Neurology.

[43]  A. Laupacis,et al.  Population rates of hospitalization for atrial fibrillation/flutter in Canada. , 2004, The Canadian journal of cardiology.

[44]  R. Tamblyn,et al.  Validation of diagnostic codes within medical services claims. , 2004, Journal of clinical epidemiology.

[45]  Stephen H. D. Jackson,et al.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. , 2003, British journal of clinical pharmacology.

[46]  R Tamblyn,et al.  Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. , 2000, Journal of clinical epidemiology.

[47]  A R Levy,et al.  Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. , 1999, The Canadian journal of cardiology.

[48]  A Bouckaert,et al.  Practical considerations on the use of the Charlson comorbidity index with administrative data bases. , 1996, Journal of clinical epidemiology.

[49]  R. Tamblyn,et al.  The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.

[50]  W. W. Brabham.  Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications for Thromboprophylaxis , 2011 .

[51]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.